Literature DB >> 8144642

Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo.

S L Friedman1, G Yamasaki, L Wong.   

Abstract

Activation of lipocytes, characterized by increased proliferation and fibrogenesis, is a central feature of the hepatic wound healing response. We have examined whether modulation of receptors for transforming growth factor beta (TGF-beta) contributes to the fibrogenic behavior of activated lipocytes. Isolated lipocytes were maintained in a quiescent state by culturing the cells in suspension, where they displayed minimal specific binding for TGF-beta 1 and only a small amount of type III (betaglycan) receptor by affinity labeling. In contrast, lipocytes activated by growth on uncoated plastic displayed saturable binding of TGF-beta 1 (Kd = 28 pM, 7,730 receptors/cell), and receptors types I, II, and III. Binding activity in quiescent and activated cells correlated with responsiveness to TGF-beta 1; TGF-beta 1 induced cellular fibronectin mRNA expression only in activated and not quiescent cells. Despite the absence of binding in quiescent cells, type II receptor was detectable by immunoblot. By RNase protection assay, mRNAs for receptor types II and III were greater in quiescent than activated cells. In freshly isolated lipocytes from animals with liver injury caused by the administration of carbon tetrachloride, a rapid but transient increase in mRNA for receptor types I (approximately 3.2-fold), II (approximately 1.5-fold), and III (approximately 3-fold) was observed with peaks at 12 h for type I receptor, 1 h for type II receptor, and 6 h for type III receptor; mRNA induction was followed by down-regulation for all receptors. The modest changes in mRNAs compared with marked alterations in binding activity during mesenchymal cell activation suggest that TGF-beta receptors may be regulated in vivo in part by a post-translational mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144642

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 2.  Transcriptional regulation of hepatic stellate cell activation.

Authors:  D A Mann; D E Smart
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

3.  Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2.

Authors:  Jianguo Lin; Anping Chen
Journal:  Mol Cell Endocrinol       Date:  2010-12-30       Impact factor: 4.102

Review 4.  Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis.

Authors:  Y Inagaki; I Okazaki
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 5.  Molecular mechanisms of hepatic fibrosis and principles of therapy.

Authors:  S L Friedman
Journal:  J Gastroenterol       Date:  1997-06       Impact factor: 7.527

6.  NEAT1 accelerates the progression of liver fibrosis via regulation of microRNA-122 and Kruppel-like factor 6.

Authors:  Fujun Yu; Zhe Jiang; Bicheng Chen; Peihong Dong; Jianjian Zheng
Journal:  J Mol Med (Berl)       Date:  2017-09-01       Impact factor: 4.599

7.  Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro.

Authors:  Shizhong Zheng; Anping Chen
Journal:  Biochem J       Date:  2004-11-15       Impact factor: 3.857

8.  Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells.

Authors:  Anping Chen
Journal:  Biochem J       Date:  2002-12-15       Impact factor: 3.857

9.  Contribution of hepatic parenchymal and nonparenchymal cells to hepatic fibrogenesis in biliary atresia.

Authors:  G A Ramm; V G Nair; K R Bridle; R W Shepherd; D H Crawford
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.